Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Autorzy:
Choi YH; Quratis Inc., Seoul, Republic of Korea. Kang YA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Institute of Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. Park KJ; Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Republic of Korea. Choi JC; Pulmonology Department, Chung-Ang University Hospital, Seoul, Republic of Korea. Cho KG; Quratis Inc., Seoul, Republic of Korea. Ko DY; Quratis Inc., Seoul, Republic of Korea. Ahn JH; Quratis Inc., Seoul, Republic of Korea. Lee B; Quratis Inc., Seoul, Republic of Korea. Ahn E; Quratis Inc., Seoul, Republic of Korea. Woo YJ; Quratis Inc., Seoul, Republic of Korea. Jung K; Quratis Inc., Seoul, Republic of Korea. Kim NY; Quratis Inc., Seoul, Republic of Korea. Reese VA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Larsen SE; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. BaldwinSL; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Reed SG; HDT Bio, Seattle, WA, USA. Coler RN; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. .; Department of Global Health, University of Washington, Seattle, WA, USA. .; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA. . Lee H; Quratis Inc., Seoul, Republic of Korea. .; Institute of Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. .; Division of Vaccine Research, International Tuberculosis Research Center, Seoul, Republic of Korea. . Cho SN; Quratis Inc., Seoul, Republic of Korea. .; Institute of Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
Infectious diseases and therapy [Infect Dis Ther] 2023 Jun; Vol. 12 (6), pp. 1605-1624. Date of Electronic Publication: 2023 May 11.
Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration.
Autorzy:
Maloney SE; Technology Advancement and Commercialization, RTI International, Research Triangle Park, NC 27709, USA. Stewart IE; Technology Advancement and Commercialization, RTI International, Research Triangle Park, NC 27709, USA. Podell BK; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA. Gary HE; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA. Mecham JB; Technology Advancement and Commercialization, RTI International, Research Triangle Park, NC 27709, USA. Berube BJ; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA 98109, USA. BaldwinSL; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA 98109, USA. Coler RN; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA 98109, USA.; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA.; Department of Global Health, University of Washington, Seattle, WA 98195, USA. Hickey AJ; Technology Advancement and Commercialization, RTI International, Research Triangle Park, NC 27709, USA.
Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.
Autorzy:
Larsen SE; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Reese VA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Pecor T; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Berube BJ; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. Cooper SK; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA. Brewer G; Alternative Behavior Strategies Inc, Salt Lake City, UT, USA. Ordway D; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA. Henao-Tamayo M; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA. Podell BK; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA. BaldwinSL; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. susan.baldwin@seattlechildrens.org. Coler RN; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Apr 27; Vol. 11 (1), pp. 9040. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
Autorzy:
BaldwinSL; Seattle Children's Research Institute, Seattle, WA, United States of America. Reese VA; Seattle Children's Research Institute, Seattle, WA, United States of America. Larsen SE; Seattle Children's Research Institute, Seattle, WA, United States of America. Beebe E; Infectious Disease Research Institute, Seattle, WA, United States of America. Guderian J; Infectious Disease Research Institute, Seattle, WA, United States of America. Orr MT; Infectious Disease Research Institute, Seattle, WA, United States of America. Fox CB; Infectious Disease Research Institute, Seattle, WA, United States of America.; Department of Global Health, University of Washington, Seattle, WA, United States of America. Reed SG; Infectious Disease Research Institute, Seattle, WA, United States of America. Coler RN; Seattle Children's Research Institute, Seattle, WA, United States of America.; Department of Global Health, University of Washington, Seattle, WA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Mar 11; Vol. 16 (3), pp. e0247990. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
Autorzy:
Kwon KW; Department of Microbiology, Institute for Immunology and Immunological Disease, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea. Lee A; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, 03722, South Korea. Larsen SE; Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, USA. BaldwinSL; Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, USA. Coler RN; Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, USA.; Department of Global Health, University of Washington, Seattle, USA.; PAI Life Sciences Inc., Seattle, USA. Reed SG; Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, WA, 98102, USA. Cho SN; Department of Microbiology, Institute for Immunology and Immunological Disease, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea. Ha SJ; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, 03722, South Korea. Shin SJ; Department of Microbiology, Institute for Immunology and Immunological Disease, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Oct 29; Vol. 9 (1), pp. 15560. Date of Electronic Publication: 2019 Oct 29.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.
Autorzy:
BaldwinSL; Infectious Disease Research Institute, Seattle, Washington, United States of America. Larsen SE; Infectious Disease Research Institute, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America. Ordway D; Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America. Cassell G; Infectious Disease Research Institute, Seattle, Washington, United States of America.; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America. Coler RN; Infectious Disease Research Institute, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America.; PAI Life Sciences, Seattle, Washington, United States of America.
Pokaż więcej
Źródło:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2019 Feb 14; Vol. 13 (2), pp. e0007083. Date of Electronic Publication: 2019 Feb 14 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.
Autorzy:
Van Hoeven N; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Fox CB; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Granger B; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Evers T; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Joshi SW; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Nana GI; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Evans SC; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Lin S; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Liang H; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Liang L; University of California Irvine, Department of Medicine, Irvine CA 92697, USA. Nakajima R; University of California Irvine, Department of Medicine, Irvine CA 92697, USA. Felgner PL; University of California Irvine, Department of Medicine, Irvine CA 92697, USA. Bowen RA; Colorado State University Department of Biomedical Sciences, Foothills Campus, Fort Collins, CO 80523, USA. Marlenee N; Colorado State University Department of Biomedical Sciences, Foothills Campus, Fort Collins, CO 80523, USA. Hartwig A; Colorado State University Department of Biomedical Sciences, Foothills Campus, Fort Collins, CO 80523, USA. BaldwinSL; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Coler RN; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Tomai M; 3M, Inc., St. Paul, Minnesota 55121, USA. Elvecrog J; 3M, Inc., St. Paul, Minnesota 55121, USA. Reed SG; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA. Carter D; Infectious Disease Research Institute, 1616 Eastlake Ave E., Seattle WA 98103, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2017 Apr 21; Vol. 7, pp. 46426. Date of Electronic Publication: 2017 Apr 21.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
